US Food and Drug Administration Approval: Ruxolitinib for the Treatment of Patients with intermediate andhigh Risk Myelofibrosis Full Text
Clinical Cancer Research, 05/01/2012
Deisseroth AB et al. – On November 16, 2011, Food and Drug Administration (FDA) granted full approval to ruxolitinib for the treatment of patients with intermediate or high risk myelofibrosis. This is the first drug approved for myelofibrosis (MF).